Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers’ Precancer Lesions with Microsatellite Instability Elisa Micarelli, Lorenzo De Marco, Paola Spaggiari, Anna Morena D’Alise, Arianna Dal Buono, Maddalena Menini, Valentina Giatti, Alessandro D’Aprano, Elisa Scarselli, Cesare Hassan, Alessandro Repici Cancer Prevention Research, 2026 This study provides a molecular characterization of precancerous colorectal lesions in Lynch syndrome (LS) carriers to assess the preventive potential of Nous-209 immunotherapy against colorectal cancer development. A total of 50 adenomas and 12 advanced adenomas (AA) were collected from 26 LS carriers with pathogenic variants in either MLH1 or MSH2. Molecular analyses included assessment of mismatch repair (MMR) status, microsatellite instability (MSI), and detection of mutations targeted by Nous-209. We found that 83% of AAs and 58% of adenomas were MMR-deficient (dMMR). Notably, although all dMMR AA were MSI-high (MSI-H), only 66% of dMMR adenomas showed MSI-H. The presence of Nous-209 mutations correlated strongly with MSI status, with mutation counts ranging from 15 to 57 in dMMR/MSI-H lesions. dMMR adenomas classified as MSI-low carried a limited number of mutations (6–19), whereas microsatellite-stable lesions harbored very few (0–2) Nous-209 mutations, regardless of MMR proficiency. These findings confirm the molecular heterogeneity of precancerous lesions and support the potential of Nous-209 immunotherapy to prevent MSI colorectal cancer in LS by targeting the adenoma–carcinoma sequence at the time of MSI acquisition. Prevention Relevance: Our study shows that MSI and neoantigen accumulation emerge during the evolution of precancerous lesions in LS. These findings support the clinical evaluation of Nous-209, a shared neoantigen vaccine, as an immunoprevention strategy for MSI-driven colorectal carcinogenesis, with important implications for cancer prevention research.
Peri-operative fasting in adults: an international, multidisciplinary consensus statement Anne Rüggeberg, Kariem El‐Boghdadly, Federico Bilotta, Marta Dias Vaz, Anne Marie Camilleri Podesta, Ib Jammer, Ehrenfried Schindler, Jamie Elmawieh, Alexander Nagrebetsky, Stakeholders Anaesthesia, 2026 Summary Introduction Evidence suggests that existing pre‐operative fasting guidelines are associated with prolonged fasting times. Prolonged fasting, particularly from clear liquids, has the potential to harm patients through reduced peri‐operative wellbeing; impaired glucose metabolism and peri‐operative inflammatory response; delayed return of bowel function; and reduced muscle strength. Liberalisation of fasting practices has, therefore, become increasingly common. Such a change in practice dictates the need for updated practice guidance. We aimed to develop recommendations on peri‐operative fasting that reflect increasing global awareness of the adverse effects of prolonged fasting. Methods Following a systematic literature review, 13 draft recommendations related to peri‐operative fasting were developed iteratively. These were modified during a three‐round Delphi process by an international, multidisciplinary stakeholder panel, which included: patients; anaesthetists; surgeons; physicians; nurses; and members of relevant international organisations from five continents. Results Sixty‐eight stakeholders participated in the Delphi consensus process. The panel subsequently agreed on eight recommendations. We recommend continuing current practices on pre‐operative fasting for solid food and non‐clear liquids. We recommend encouraging clear liquids until 2 h before the start of anaesthesia or sedation, unless institutional protocols allow for more liberal liquid intake. We further recommend implementation of institutional protocols that allow more liberal clear liquid intake < 2 h before the start of anaesthesia or sedation. Salivation stimulants can be used until transfer for the procedure. Oral intake should be resumed as soon as clinically feasible. Preprocedural gastric ultrasound performed by a trained provider may be used to guide clinical decisions when additional information is required. Discussion This international, multidisciplinary consensus statement aims to improve the quality of patient care by minimising periprocedural fasting times, within safe margins. To achieve this, liberalised pre‐operative clear liquid intake regimens may be implemented with institutional protocols.
Learning curve in intestinal ultrasound: advancing from basic skills to advanced competencies–insights from the IUS IG-IBD Master program Cristina Bezzio, Luisa Bertin, Simone Saibeni, Davide Giuseppe Ribaldone, Federica Furfaro, Giovanni Maconi, Fulvia Terracciano, Elena Mazzotta, Emma Calabrese, Fabiana Castiglione, Ambrogio Orlando, Giuseppe Privitera, Sara Massironi, Francesca Zorzi, Lorena Pirola, Silvio Danese, Antonio Rispo, Flavio Caprioli, Mirella Fraquelli, Demis Pitoni, Arianna Dal Buono, Anna Testa, Massimo Claudio Fantini, Alessandro Armuzzi, Mariangela Allocca, Collaborators, Nicola Imperatore, Marta Vernero, Simona Ricciolino, Manuela Marzo, Alessia Guarino, Valentino Calvez, Alessia Todeschini, Elena Bartolini, Emanuele Orlando, Caterina Zoratti, Gaia Riguccio Journal of Crohn S and Colitis, 2026 Background Intestinal ultrasound (IUS) is increasingly valuable in inflammatory bowel disease (IBD) management. Objective This study aimed to determine the learning curve for basic and advanced IUS parameters and establish the minimum number of examinations required for diagnostic proficiency. Design We conducted a prospective, multicenter study across eight Italian tertiary IBD centers. Eight gastroenterology trainees with extensive abdominal ultrasound experience but limited IUS exposure completed standardized training comprising theoretical education, 30 supervised examinations, and 99 independent assessments. Expert sonographers independently and blindly reassessed all independent examinations using identical protocols. Interobserver agreement was quantified using Cohen’s kappa coefficients across 12 predefined categories, stratified into basic (bowel wall thickness, vascularity, stratification) and advanced (fistulas, collections, strictures) findings. Results Following initial training, trainees demonstrated substantial baseline competency. Basic parameters achieved consistently high performance throughout the study period (from κ = 0.792 to κ = 0.842), while advanced findings showed more pronounced learning curves, improving from κ = 0.728 to κ = 0.854. Small bowel dilation exhibited the steepest learning trajectory (κ = 0.674 to κ = 0.921, 36.6% improvement, P = .204). Sustained primary competence (κ ≥ 0.8) was achieved by 37.5-62.5% of trainees for basic parameters within 99 examinations, with bowel wall stratification proving most challenging (37.5% success rate). Conclusion This study establishes the first comprehensive, parameter-specific learning thresholds for IUS competency in IBD. Our findings demonstrate that structured training enables basic IUS proficiency within 69-112 examinations for experienced ultrasonographers, while advanced skills require extended practice. These data represent an important step toward defining evidence-based benchmarks for IUS training, supporting the development of standardized international curricula and safe clinical implementation.
New Technologies for IBD Endoscopy Cristina Bezzio, Valeria Farinola, Giuseppe Privitera, Arianna Dal Buono, Roberto Gabbiadini, Laura Loy, Gianluca Franchellucci, Erica Bartolotta, Giulia Migliorisi, Alessandro Armuzzi Journal of Clinical Medicine, 2026 Background: Endoscopic assessment is central to the management of inflammatory bowel disease (IBD), particularly within treat-to-target strategies. However, conventional high-definition white-light endoscopy (HD-WLE) is limited by interobserver variability and its inability to reliably reflect microscopic inflammation or predict long-term outcomes. Over the last decade, multiple technological innovations have reshaped the role of endoscopy in both disease activity monitoring and dysplasia surveillance. Methods: This narrative review provides a comprehensive and clinically oriented overview of emerging endoscopic technologies in IBD, including image-enhanced endoscopy, ultra-high-magnification techniques, artificial intelligence (AI), and molecular imaging. We discuss their diagnostic performance, prognostic implications, and potential integration into clinical practice. Results: Image-enhanced endoscopy improves visualization of subtle mucosal and vascular alterations and demonstrates stronger correlation with histological activity compared with HD-WLE alone. Confocal laser endomicroscopy and endocytoscopy enable in vivo microscopic assessment of epithelial architecture and barrier integrity, redefining remission beyond macroscopic healing. AI systems have shown expert-level performance in grading inflammatory severity in ulcerative colitis and high sensitivity in capsule endoscopy for Crohn’s disease, supporting objective and reproducible assessment. In surveillance, targeted high-definition inspection has replaced random biopsies, while adjunctive optical and AI-based tools enhance lesion detection and characterization. Molecular imaging introduces a predictive dimension by enabling visualization of drug–target engagement and dysplasia-specific pathways. Conclusions: Endoscopy in IBD is evolving from a descriptive modality toward a multimodal precision tool integrating enhanced imaging, AI-driven standardization, and molecular profiling. Although further validation and cost-effectiveness studies are required, these innovations have the potential to improve therapeutic stratification, surveillance strategies, and long-term patient outcomes.
Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis—the TACTIC-UC study Giuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, Roberto Gabbiadini, Laura Loy, Luca Ranucci, Luisa Bertin, Benedetta Masoni, Giulia Migliorisi, Elisabetta Sauta, Mattia Delleani, Victor Savevski, Matteo Della Porta, Saverio D’Amico, Alessandro Armuzzi Journal of Crohn S and Colitis, 2026 Background & Aims In ulcerative colitis (UC), therapeutic goals are evolving beyond symptom control toward endoscopic and histologic healing. However, optimal strategies to achieve these targets are undefined, and the implementation of treat-to-target (T2T) in patients with minimal symptoms despite ongoing intestinal inflammation remains unexplored. This study evaluated the real-world effectiveness of endoscopy-guided optimization in this population. Methods TACTIC-UC is a retrospective, single-centre study including UC patients undergoing endoscopy-guided optimization of anti-TNF agents, vedolizumab, or ustekinumab. Eligible cases had quiescent or mild symptoms (partial Mayo score 0-4) but moderate-to-severe endoscopic activity (endoscopic Mayo Score, eMS ≥ 2) and underwent treatment optimization within 1 month after index endoscopy. The primary outcome was mucosal healing (MH, eMS ≤ 1) within 1 year. Secondary endpoints included endoscopic remission (ER, eMS = 0), histo-endoscopic mucosal remission (HEMR, eMS = 0 + Nancy Index = 0-1), biomarker trends, steroid use, adverse events, and treatment persistence. Results A total of 164 optimization episodes were analysed in 142 patients. The 1-year cumulative probabilities of MH, ER, and HEMR were 54.2%, 28.8%, and 20.9%, respectively. In weighted analyses, anti-TNF-α therapies outperformed non-anti-TNF-α agents (vedolizumab and ustekinumab pooled together) across all outcomes: 66.3% versus 45.0% for MH, 39.3% versus 19.8% for ER, and 33.2% versus 8.1% for HEMR (all P-values &lt; 0.05); consistent trends were confirmed in an exploratory 3-arm analysis incorporating synthetic data augmentation. Baseline steroid use and an eMS of 3 were independently associated with reduced probability of achieving endoscopic and histologic outcomes. No safety signals emerged. Endoscopic and histologic outcomes were associated with improved treatment persistence. Conclusions In UC patients with quiescent or mild symptoms but active endoscopic inflammation, endoscopy-guided optimization of biologics is effective in achieving deeper inflammatory control, supporting its integration into T2T strategies.
Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer Salvatore Paiella, Erica Secchettin, Livia Archibugi, Raffaele De Luca, Cristiana Bonifacio, Luigi Laghi, Gabriella Lionetto, Anna Caterina Milanetto, Giuliana Sereni, Chiara Coluccio, Gaetano Lauri, Arianna Dal Buono, Margherita Patruno, Giulia Gabriel, Romano Sassatelli, Cecilia Binda, Deborah Bonvissuto, Vera Uliana, Giuseppe Malleo, Giulia Martina Cavestro, Maria Terrin, Stefania Martino, Claudio Pasquali, Matteo De Pastena, Francesco De Cobelli, Valeria Poletti, Elisa Venturini, Marta Puzzono, Alessandro Zerbi, Paolo Giorgio Arcidiacono, Roberto Salvia, Massimo Falconi, Gabriele Capurso, Silvia Carrara United European Gastroenterology Journal, 2026 Background Little is known about the genetic background of individuals with familial pancreatic cancer (PC). Integrating germline testing into surveillance may uncover previously unrecognized hereditary susceptibility and expand prevention strategies beyond BRCA testing alone. This study evaluated the genetic landscape of high‐risk individuals due to familiality (HRI‐FHs) enrolled in a national surveillance program. Methods Five hundred HRI‐FHs from seven centers underwent surveillance and germline testing with a 41‐gene NGS panel. Pathogenic/likely pathogenic variants (PGVs) and variants of unknown significance (VUS) were identified and correlated with clinical and imaging findings. Results Overall, forty‐four (8.8%) out of 500 HRI‐FHs carried at least one PGV, including 3.4% in high‐penetrance genes ( ATM, BRCA1/2, PALB2, BRIP1 ). Notably, 8 out of 17 (47%) of ATM , BRCA1/2, PALB2 carriers would not have met the national testing criteria based solely on their family history. An additional 5.4% (27/500) carried PGVs in genes linked to other hereditary conditions ( CFTR, MUTYH, CTRC, SPINK1, APC ), and 39.6% harbored at least one VUS. PGV status, age, and female gender were independent predictors of radiological abnormalities. Two PCs were diagnosed, both in mutation‐negative individuals. Discussion Integrating germline testing into surveillance redefines the management of familial PC. It uncovers hereditary susceptibility beyond classical criteria and supports cascade testing. PC also arises in mutation‐negative HRI. #NCT05724992.
Sustainable monitoring in inflammatory bowel disease: comparative carbon, energy, waste, and cost impact of intestinal ultrasound versus colonoscopy Arianna Dal Buono, Roberto Gabbiadini, Giuseppe Privitera, Benedetta Masoni, Matteo Spertino, Giulia Migliorisi, Gianluca Franchellucci, Laura Loy, Alessandro Repici, Cristina Bezzio, Alessandro Armuzzi Digestive and Liver Disease, 2026 BACKGROUND: Treat-to-target strategies in inflammatory bowel disease (IBD) rely on repeated objective assessments, leading to frequent colonoscopy for therapeutic decision-making. Although effective, endoscopic monitoring is resource-intensive and may not be necessary in all stable patients. AIMS: To evaluate the environmental and economic impact of intestinal ultrasound (IUS) compared with colonoscopy for therapeutic monitoring in IBD. METHODS: In this single-center retrospective cohort (2022-2024), 200 adults with IBD undergoing both IUS and colonoscopy were analyzed. The functional unit was one monitoring episode. For each modality, we quantified carbon dioxide equivalent emissions (CO₂e), energy use (kWh), and disposable waste (g) within defined system boundaries. Procedure cost was assessed as a secondary outcome. A patient-level model projected cumulative impact across ten monitoring cycles, comparing an IUS + fecal calprotectin (FCP >250 μg/g) strategy with colonoscopy-for-all. RESULTS: Per procedure, colonoscopy required +0.91 kWh, emitted +2.9 kg CO₂e, and generated +212 g disposables versus IUS (all p<0.001). IUS reduced energy use by ∼95%, CO₂e by ∼100-fold, and disposables by ∼85%. Over ten cycles, an IUS-first strategy reduced cumulative CO₂e emissions and costs by ∼40% (both p<0.05). CONCLUSIONS: IUS substantially lowers environmental and economic burden compared with colonoscopy while supporting timely therapeutic decisions. An IUS + FCP-first approach represents a pragmatic, sustainable monitoring strategy in IBD.
Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis Giuseppe Privitera, Cristina Bezzio, Gisella Figlioli, Ferdinando D’Amico, Joao Mendes, Simone Varca, Fabiana Zingone, Iago Rodriguez-Lago, Sara Onali, Flavio A. Caprioli, María Chaparro, Manuel Barreiro-de-Acosta, Konstantinos Karmiris, Natalie Tamir Degabli, Lior Dar, Luca Pastorelli, Ana Gutiérrez, Ambrogio Orlando, Yamile Zabana, Simone Saibeni, Daniele Piovani, Edoardo V. Savarino, Daniela Pugliese, Fernando Magro, Silvio Danese, Alessandro Armuzzi, Stefanos Bonovas, Fabrizio Fanizzi, Paula Ferraz, Franco Scaldaferri, Brigida Barberio, Irene Moraleja, Agnese Favale, Daniele Noviello, Javier P. Gisbert, Marisol Porto-Silva, Andreas Psistakis, Henit Yanai, Uri Kopylov, Mattia Di Pietro, Lucía Madero-Velázquez, Fabio Salvatore Macaluso, Rosalba Orlando, Roberto Gabbiadini, Arianna Dal Buono, Laura Loy, Giulia Migliorisi, Caterina Zoratti Clinical Gastroenterology and Hepatology, 2026 BACKGROUND & AIMS: With the advent of agents targeting distinct inflammatory pathways, therapeutic sequencing after anti-tumor necrosis factor alpha (TNF-α) failure in ulcerative colitis (UC) represents a major challenge. We compared the real-world effectiveness and safety of vedolizumab, ustekinumab, and Janus kinase inhibitors (JAKis) in anti-TNF-α-exposed patients. METHODS: In this retrospective, multicenter European study, adults with UC initiating second-line vedolizumab, ustekinumab, or a JAKi after anti-TNF-α were evaluated. Baseline confounding was addressed by applying energy balancing weights (EBWs). Effectiveness outcomes included probability of steroid-free clinical remission (SFCR) and biochemical SFCR at 12 months, analyzed using EBW-weighted Royston-Parmar survival models to derive adjusted time-averaged hazard ratios (aHRs). Adverse event (AE) rates were compared using EBW-weighted Poisson regression. RESULTS: A total of 596 patients were included (301 vedolizumab, 149 ustekinumab, 146 JAKi); 54.7% were male, with a mean age of 43.9 ± 15.5 years. Clinical activity, endoscopic scores, and biomarker levels were broadly comparable across treatment groups. Infliximab was the most common prior anti-TNF-α (74.8%), and secondary failure was the predominant discontinuation reason (47.3%). Compared with vedolizumab, both ustekinumab and JAKi showed significantly higher probability of SFCR (aHR, 1.54; 95% confidence interval [CI], 1.09-2.07; and aHR, 1.66; 95% CI, 1.07-2.53, respectively) and biochemical SFCR (aHR, 2.26; 95% CI, 1.48-3.28 and 3.37; 95% CI, 2.01-5.36, respectively) at 12 months, with no differences between them. JAKi recipients experienced an approximately 4-fold higher incidence of AEs, compared with both vedolizumab and ustekinumab, with no differences between ustekinumab and vedolizumab. CONCLUSIONS: Ustekinumab and JAKi were more effective than vedolizumab in inducing steroid-free and biochemical remission following anti-TNF-α failure. Safety concerns with JAKi warrant careful patient selection in clinical practice. CLINICALTRIALS: gov, Number: NCT06691061.
Variability and performance of radiologic stricture parameters in Crohn's disease: a systematic review and meta-analysis Arianna Dal Buono, Francesco Faita, Sarah Bencardino, Giacomo Maiucci, Alberto Barchi, Alessandro Armuzzi, Dominik Bettenworth, Silvio Danese, Mariangela Allocca Eclinicalmedicine, 2025 Background Disease-related strictures are a common complication of Crohn's disease (CD). Cross-sectional imaging is widely used for their assessment, but definitions remain variable and non-standardised. This systematic review and meta-analysis aimed to identify commonly used imaging parameters, assess diagnostic performance, and evaluate consistency across studies. Methods We conducted a systematic review of ultrasound (US), magnetic resonance imaging (MRI), and computed tomography (CT) studies on CD-associated strictures, searching MEDLINE/PubMed, Embase, and Cochrane to January 1, 2025. We included prospective and retrospective studies of small-bowel CD strictures with surgical histopathology as reference standard. Summary data were extracted from published reports and pooled using a random-effects bivariate meta-analysis, which jointly models sensitivity and specificity while accounting for between-study heterogeneity. Exclusion criteria were pediatric populations, colonic and upper-GI strictures. Main outcomes were stricture definitions and diagnostic performance. The study is registered with PROSPERO, CRD420251032918. Findings Of the 9436 articles identified through the search, 30 met eligibility criteria and were included in the analysis, comprising 1866 patients with CD: 5 on US, 7 on CT, 8 on MRI, and the remaining assessed two techniques. Luminal narrowing (LN), bowel wall thickening (BWT), and pre-stenotic dilation (PSD) were the most common descriptors. 4 studies (13%) required all three; the remaining used LN or BWT alone, with PSD often considered optional (20/30 [77%]). Overall, 26.7% (8/30) of studies were judged at high or unclear risk of bias in at least one domain. Pooled sensitivity and specificity for US techniques to detect strictures were 0.88 (95% CI, 0.83–0.91) and 0.86 (95% CI, 0.79–0.91) ( I 2 = 0%), respectively. Pooled sensitivity and specificity for MRE were 0.82 (95% CI, 0.69–0.90) and 0.80 (95% CI, 0.44–0.95) ( I 2 = 61.2%), and for CTE were 0.83 (95% CI, 0.73–0.90) and 0.77 (95% CI, 0.47–0.93) ( I 2 = 58.8%), respectively. Interpretation High diagnostic accuracy was observed across imaging modalities, with no statistically significant difference among them, and only a minority of studies at risk of bias unlikely to affect these findings. Heterogeneity existed in cut-offs and parameter combinations used to define strictures. PSD does not appear essential for stricture diagnosis, which could simplify diagnostic protocols. Variations in histological criteria and limited evidence for some modalities may limit generalizability. Funding None.
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study Ferdinando D'Amico, Luca Massimino, Giulia Palmieri, Arianna Dal Buono, Roberto Gabbiadini, Benedicte Caron, Paula Moreira, Isabel Silva, Maia Bosca‐Watts, Tommaso Innocenti, Gabriele Dragoni, Cristina Bezzio, Alessandra Zilli, Federica Furfaro, Simone Saibeni, María Chaparro, María José García, George Michalopoulos, Nikos Viazis, Gerassimos J. Mantzaris, Pierre Ellul, Javier P. Gisbert, Fernando Magro, Laurent Peyrin‐Biroulet, Alessandro Armuzzi, Federica Ungaro, Silvio Danese, Gionata Fiorino, Mariangela Allocca European Journal of Clinical Investigation, 2024
An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial Oswaldo Ortiz, Maria Daca-Alvarez, Liseth Rivero-Sanchez, Antonio Z Gimeno-Garcia, Marta Carrillo-Palau, Victoria Alvarez, Alejandro Ledo-Rodriguez, Luigi Ricciardiello, Chiera Pierantoni, Robert Hüneburg, Jacob Nattermann, Raf Bisschops, Sabine Tejpar, Alain Huerta, Faust Riu Pons, Cristina Alvarez-Urturi, Jorge López-Vicente, Alessandro Repici, Cessare Hassan, Lucia Cid, Giulia Martina Cavestro, Cristina Romero-Mascarell, Jordi Gordillo, Ignasi Puig, Maite Herraiz, Maite Betes, Jesús Herrero, Rodrigo Jover, Francesc Balaguer, Maria Pellisé, Sabela Carballal, Leticia Moreira, Sonia Torres, Hardeep Kumari, Angelo Brunori, Ariadna Sanchez, Teresa Ocaña, Joaquin Castillo, Karmele Saez-Gordoa, Miriam Cuatrecasas, Eva Rivas, Maria Vizuete, Silvia Carnicer, Rosa Cuadrado, Marta Puzzono, Paolo Bianchi, Luigi Laghi, Arianna Dal Buono, Valentina Giatti, Rosangela Nicoletti, Tim Marwitz, Katrin Van Beekum, Carolina Mangas-Sanjuan, Juan Martinez-Sempere, Eva Serrano, Cristina Carretero Lancet Gastroenterology and Hepatology, 2024
Rates of Adverse Events in Patients with Ulcerative Colitis Undergoing Colectomy during Treatment with Tofacitinib vs Biologics: A Multicenter Observational Study Gabriele Dragoni, Tommaso Innocenti, Aurelién Amiot, Fabiana Castiglione, Laura Melotti, Stefano Festa, Edoardo Vincenzo Savarino, Marie Truyens, Konstantinos Argyriou, Daniele Noviello, Tamas Molnar, Vincent Bouillon, Cristina Bezzio, Piotr Eder, Samuel Fernandes, Anna Kagramanova, Alessandro Armuzzi, Raquel Oliveira, Anna Viola, Davide Giuseppe Ribaldone, Ioannis Drygiannakis, Chiara Viganò, Francesca Calella, Antonietta Gerarda Gravina, Daniela Pugliese, María Chaparro, Pierre Ellul, Sophie Vieujean, Monica Milla,, Flavio Caprioli American Journal of Gastroenterology, 2024
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium M.V. Lenti, D.G. Ribaldone, F. Borrelli de Andreis, M. Vernero, B. Barberio, M. De Ruvo, E.V. Savarino, T. Kav, A. Blesl, M. Franzoi, H.P. Gröchenig, D. Pugliese, G. Ianiro, S. Porcari, G. Cammarota, A. Gasbarrini, R. Spagnuolo, P. Ellul, K. Foteinogiannopoulou, I. Koutroubakis, K. Argyriou, M. Cappello, A. Jauregui-Amezaga, M.G. Demarzo, N. Silvestris, A. Armuzzi, F. Sottotetti, L. Bertani, S. Festa, P. Eder, P. Pedrazzoli, A. Lasagna, A. Vanoli, G. Gambini, G. Santacroce, C.M. Rossi, M. Delliponti, C. Klersy, G.R. Corazza, A. Di Sabatino, C. Mengoli, N. Aronico, F. Lepore, G. Broglio, S. Merli, G. Natalello, E. Alimenti, D. Scalvini, S. Muscarella, F. Agustoni, A. Pagani, S. Chiellino, S. Corallo, V. Musella, R. Cannizzaro, M. Vecchi, F. Caprioli, R. Gabbiadini, A. Dal Buono, A. Premoli, L.D. Locati, A. Buda, A. Contaldo, A. Schiepatti, F. Biagi, D. Morano, M. Cucè, A. Kotsakis, G. De Lisi ESMO Open, 2024
Management of Post-Operative Crohn’s Disease: Knowns and Unknowns Matteo Spertino, Roberto Gabbiadini, Arianna Dal Buono, Anita Busacca, Gianluca Franchellucci, Giulia Migliorisi, Alessandro Repici, Antonino Spinelli, Cristina Bezzio, Alessandro Armuzzi Journal of Clinical Medicine, 2024
Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer Salvatore Paiella, Gabriele Capurso, Silvia Carrara, Erica Secchettin, Fabio Casciani, Isabella Frigerio, Alessandro Zerbi, Livia Archibugi, Cristiana Bonifacio, Giuseppe Malleo, Giulia Martina Cavestro, Monica Barile, Alberto Larghi, Daniela Assisi, Alberto Fantin, Anna Caterina Milanetto, Carlo Fabbri, Riccardo Casadei, Giulio Donato, Romano Sassatelli, Giulia De Marchi, Francesco Maria Di Matteo, Valentina Arcangeli, Francesco Panzuto, Marta Puzzono, Arianna Dal Buono, Raffaele Pezzilli, Roberto Salvia, Gianenrico Rizzatti, Marco Casadio, Monica Franco, Giovanni Butturini, Claudio Pasquali, Chiara Coluccio, Claudio Ricci, Noemi Cicchese, Giuliana Sereni, Nicolò de Pretis, Serena Stigliano, Britt Rudnas, Matteo Marasco, Gabriella Lionetto, Paolo Giorgio Arcidiacono, Maria Terrin, Anna Crovetto, Alessandro Mannucci, Luigi Laghi, Claudio Bassi, Massimo Falconi American Journal of Gastroenterology, 2024
Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease Pierre Ellul, John Schembri, Andrea Vella Baldacchino, Tamas Molnár, Tamas Resal, Mariangela Allocca, Federica Furfaro, Arianna Dal Buono, Angeliki Theodoropoulou, Maria Fragaki, Emmanouela Tsoukali, Gerassimos J Mantzaris, Frank M Phillips, Shellie Radford, Gordon Moran, Haidee Gonzalez, Shaji Sebastian, Fotios Fousekis, Dimitrios Christodoulou, Ifat Snir, Zlata Lerner, Henit Yanai, Georgios Michalopoulos, Julia Tua, Liberato Camilleri, Kostas Papamichael, Konstantinos Karmiris, Konstantinos Katsanos Journal of Crohn S and Colitis, 2023
Artificial intelligence and inflammatory bowel disease: Where are we going? Leonardo Da Rio, Marco Spadaccini, Tommaso Lorenzo Parigi, Roberto Gabbiadini, Arianna Dal Buono, Anita Busacca, Roberta Maselli, Alessandro Fugazza, Matteo Colombo, Silvia Carrara, Gianluca Franchellucci, Ludovico Alfarone, Antonio Facciorusso, Cesare Hassan, Alessandro Repici, Alessandro Armuzzi World Journal of Gastroenterology, 2023
Recent advances in the use of ultrasound in Crohn’s disease Alberto Barchi, Ferdinando D’Amico, Alessandra Zilli, Federica Furfaro, Tommaso Lorenzo Parigi, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese, Arianna Dal Buono, Mariangela Allocca Expert Review of Medical Devices, 2023
Juvenile polyposis syndrome: An overview Arianna Dal Buono, Federica Gaiani, Laura Poliani, Luigi Laghi Best Practice and Research Clinical Gastroenterology, 2022
